Comparative Analysis of the Combined Therapeutic Effects of Lipoprostaglandin E1 on Sudden Idiopathic Sensorineural Hearing Loss
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Objectives: Viral and vascular disorders are considered to be a major cause of idiopathic sudden sensorineural hearing loss (ISSNHL). Lipoprostaglandin E1 (lipo- PGE1) has vasodilating activity and has been used to treat ISSNHL. The purpose of this study was to determine the specific therapeutic effects of lipo-PGE1 and compare them to other treatment modalities for ISSNHL. Subjects and Methods: The study group had 1,052 patients diagnosed with ISSNHL. All were treated with steroid, carbogen inhalation, stellate ganglion block (SGB), or PGE1. The CP group (steroid, carbogen inhalation, and PGE1 injection; 288 patients) was treated with lipo-PGE1 and carbogen inhalation, the CS group (steroid, carbogen inhalation, and stellate ganglion block; 232 patients) with steroid, carbogen inhalation, and SGB, the C group (steroid and carbogen inhalation; 284 patients) with steroid and carbogen, and the control group (steroid only; 248 patients) with steroid only. Patients in the groups receiving lipo-PGE1 received a continuous infusion of 10 μL lipo-PGE1. Results: The overall recovery rate after treatment was 52.2%, and recovery rates by group were 67.7% in the CP group, 54.3% in the CS group, 52.1% in the C group, and 32.2% in the control group. Therefore, the therapeutic results in groups treated with lipo-PGE1 were better than results in other groups. The difference was statistically significant. Conclusions: The study results suggested that the CP group received effective treatment modalities for ISSNHL. The combined therapy of lipo-PGE1 with carbogen inhalation in patients with ISSNHL was more beneficial than other treatment modalities.
Abstract
Background and Objectives: Viral and vascular disorders are considered to be a major cause of idiopathic sudden sensorineural hearing loss (ISSNHL). Lipoprostaglandin E1 (lipo- PGE1) has vasodilating activity and has been used to treat ISSNHL. The purpose of this study was to determine the specific therapeutic effects of lipo-PGE1 and compare them to other treatment modalities for ISSNHL. Subjects and Methods: The study group had 1,052 patients diagnosed with ISSNHL. All were treated with steroid, carbogen inhalation, stellate ganglion block (SGB), or PGE1. The CP group (steroid, carbogen inhalation, and PGE1 injection; 288 patients) was treated with lipo-PGE1 and carbogen inhalation, the CS group (steroid, carbogen inhalation, and stellate ganglion block; 232 patients) with steroid, carbogen inhalation, and SGB, the C group (steroid and carbogen inhalation; 284 patients) with steroid and carbogen, and the control group (steroid only; 248 patients) with steroid only. Patients in the groups receiving lipo-PGE1 received a continuous infusion of 10 μL lipo-PGE1. Results: The overall recovery rate after treatment was 52.2%, and recovery rates by group were 67.7% in the CP group, 54.3% in the CS group, 52.1% in the C group, and 32.2% in the control group. Therefore, the therapeutic results in groups treated with lipo-PGE1 were better than results in other groups. The difference was statistically significant. Conclusions: The study results suggested that the CP group received effective treatment modalities for ISSNHL. The combined therapy of lipo-PGE1 with carbogen inhalation in patients with ISSNHL was more beneficial than other treatment modalities.
참고문헌 (28)
- Kallinen J, "Effect of carbogen inhalation on peripheral tissue perfusion and oxygenation in patients suffering from sudden hearing loss", Ann Otol Rhinol Laryngol, 108, pp.944~947 (1999)
- Choung YH, "Intratympanic dexamethasone injection for refractory sudden sensorineural hearing loss", Laryngoscope, 116, pp.747~752 (2006)
- Fetterman BL, "Prognosis and treatment of sudden sensorineural hearing loss", Am J Otol, 17, pp.529~536 (1996)
- Ahn JH, "Therapeutic effect of lipoprostaglandin E1 on sudden hearing loss", Am J Otolaryngol, 26, pp.245~248 (2005)
- Gianoli GJ, "Transtympanic steroids for treatment of sudden hearing loss", Otolaryngol Head Neck Surg, 125, pp.142~146 (2001)
- Haberkamp TJ, "Management of idiopathic sudden sensorineural hearing loss", Am J Otol, 20, pp.587~592 (1999)
- Wilson WR, "Viral and epidemiologic studies of idiopathic sudden hearing loss", Otolaryngol Head Neck Surg, 91, pp.653~658 (1983)
- 이재우, "Clinical Features and Prognosis of Sudden Sensorineural Hearing Loss Secondary to Intralabyrinthine Hemorrhage", Journal of Audiology & Otology, 20(1), pp.31~35 (2016), 대한청각학회
- Chandrasekhar SS, "Intratympanic dexamethasone for sudden sensorineural hearing loss: clinical and laboratory evaluation", Otol Neurotol, 22, pp.18~23 (2001)
- Mattox DE, "Idiopathic sudden sensorineural hearing loss", Am J Otol, 10, pp.242~247 (1989)
- Mattox DE, "Natural history of sudden sensorineural hearing loss", Ann Otol Rhinol Laryngol, 86(4 Pt 1), pp.463~480 (1977)
- Kallinen J, "Sudden deafness:a comparison of anticoagulant therapy and carbogen inhalation therapy", Ann Otol Rhinol Laryngol, 106, pp.22~26 (1997)
- 노경진, "Long-Term Outcomes of Acute Low-Tone Hearing Loss", Journal of Audiology & Otology, 19(2), pp.74~78 (2015), 대한청각학회
- 장진경, "Short-Term Outcomes of Acute Low-Tone Sensorineural Hearing Loss According to Treatment Modality", Journal of Audiology & Otology, 20(1), pp.47~52 (2016), 대한청각학회
- Doyle KJ, "Intratympanic steroid treatment: a review", Otol Neurotol, 25, pp.1034~1039 (2004)
- Alexiou C, "Sudden sensorineural hearing loss: does application of glucocorticoids make sense?", Arch Otolaryngol Head Neck Surg, 127, pp.253~258 (2001)
- Goycoolea MV, "Experimental studies on round window structure: function and permeability", Laryngoscope, 98(6 Pt 2 Suppl 44), pp.1~20 (1988)
- Parnes LS, "Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application", Laryngoscope, 109(7 Pt 2), pp.1~17 (1999)
- Hughes GB, "Sudden sensorineural hearing loss", Otolaryngol Clin North Am, 29, pp.393~405 (1996)
- Khetarpal U, "Idiopathic sudden sensorineural hearing loss and postnatal viral labyrinthitis: a statistical comparison of temporal bone findings", Ann Otol Rhinol Laryngol, 99, pp.969~976 (1990)
- Fisch U, "Measurement of oxygen tension in human perilymph", Acta Otolaryngol, 81, pp.278~282 (1976)
- Haug O, "Stellate ganglion blocks for idiopathic sensorineural hearing loss", Arch Otolaryngol, 102, pp.5~8 (1976)
- Clifford PC, "Treatment of vasospastic disease with prostaglandin E1. Treatment of vasospastic disease with prostaglandin E1", Br Med J, 281, pp.1031~1034 (1980)
- Nishimura T, "Effects of intravenous administration of prostaglandin E(1) and lipo-prostaglandin E(1) on cochlear blood flow in guinea pigs", Eur Arch Otorhinolaryngol, 259, pp.253~256 (2002)
- Murray KJ, "Cyclic AMP and mechanisms of vasodilation", Pharmacol Ther, 47, pp.329~345 (1990)
- Salganicoff L, "An hypothesis on the consolidation and PGE1-induced deconsolidation of a platelet plug", Platelets, 14, pp.463~471 (2003)
- Nakashima T, "Evaluation of prostaglandin E1therapy for sudden deafness", Laryngoscope, 99, pp.542~546 (1989)
- Ogawa K, "Effect of prostaglandin E1on idiopathic sudden sensorineural hearing loss: a double-blinded clinical study", Otol Neurotol, 23, pp.665~668 (2002)